Crosspoint Capital Strategies’s Gilead Sciences GILD Stock Holding History

Crosspoint Capital Strategies’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,260	Closed	-$124K	–	387
2015 Q4	$124K	Buy	1,260 +576	+84%	+$59.9K	0.03%	287
2015 Q3	$67K	Sell	684 -1,553	-69%	-$172K	0.08%	223
2015 Q2	$262K	Buy	2,237 +1,437	+180%	+$157K	0.07%	144
2015 Q1	$79K	Sell	800 -5,814	-88%	-$590K	0.04%	225
2014 Q4	$624K	Buy	6,614 +1,801	+37%	+$186K	0.22%	111
2014 Q3	$512K	Buy	4,813 +8	+0.2%	+$783	0.38%	63
2014 Q2	$439K	Buy	4,805 +890	+23%	+$69.3K	0.17%	98
2014 Q1	$277K	Hold	3,915	–	–	0.11%	108
2013 Q4	$325K	Buy	+3,915	New	+$273K	0.11%	113

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Crosspoint Capital Strategies's GILD Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of Gilead Sciences (GILD) in Q1 2016, closing a stake of 1,260 shares — an estimated $124K sold.

Crosspoint Capital Strategies first reported a position in GILD in Q4 2013 and held it in 9 quarters. The position peaked at $624K in Q4 2014. 1,629 funds tracked by Wall St. Rank hold GILD as of Q1 2016.

Crosspoint Capital Strategies reported no remaining Gilead Sciences position as of Q1 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 1,260 Gilead Sciences shares in Q1 2016, an estimated $124K.
Crosspoint Capital Strategies first reported a position in Gilead Sciences in Q4 2013 and held it in 9 quarters.
Crosspoint Capital Strategies's Gilead Sciences position peaked at $624K in Q4 2014.
1,629 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.